Oxygen Therapy Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Oxygen therapy is a cornerstone of respiratory care, involving the delivery of concentrated or medical-grade oxygen to patients with conditions such as COPD, asthma, pneumonia, and sleep apnea. The market encompasses a range of products including stationary and portable oxygen concentrators, compressed gas cylinders, liquid oxygen systems, masks, nasal cannulas, and related delivery accessories. The broader global oxygen market, which includes industrial grade applications, was valued at approximately $48 billion in 2025 and is projected to reach approximately $155 billion by 2035. Within the narrower medical oxygen therapy segment, North America accounted for the largest share of the medical gases market in 2025, with regional revenues driven by high healthcare spending and well-established hospital infrastructure.

• •Medical oxygen therapy market valued at approximately $43.8 billion in 2026, growing at a 5.4% CAGR; broader oxygen market at ~$48 billion in 2025 with some projections to $155 billion by 2035
• •North America represented over 37% of the global medical gases market revenue in 2025, with the U.S. medical oxygen segment valued at roughly $1.26 billion in 2024
• •Industrial oxygen segment valued at ~$64.5 billion in 2025, projected to reach ~$107 billion by 2035, reflecting wider demand beyond healthcare

The rising global prevalence of chronic respiratory diseases is the primary demand driver for oxygen therapy systems, particularly as smoking rates, air pollution levels, and occupational lung exposures remain elevated in key markets. An aging demographic profile in developed nations, where seniors represent a disproportionate share of respiratory condition diagnoses, is compounding demand for long-term home oxygen solutions. Expanding healthcare infrastructure and insurance coverage for home-based therapy across Asia-Pacific and Latin America is unlocking significant new patient populations. Meanwhile, advances in portable concentrator technology and battery efficiency are broadening the addressable market beyond institutional settings into home and ambulatory care environments.

• •Growing burden of COPD, asthma, and other respiratory illnesses globally is expanding the patient pool requiring long-term oxygen therapy
• •Home-based oxygen therapy adoption is accelerating as patients and payers favor lower-cost alternatives to inpatient treatment
• •Government and private sector investment in healthcare infrastructure across emerging markets is improving access to oxygen therapy products and services

Oxygen therapy products are typically segmented by delivery device type, including oxygen concentrators, compressed gas cylinders, liquid oxygen systems, and oxygen conserving devices, as well as by application setting (hospitals, home care, and ambulatory settings) and portability (stationary versus portable systems). Concentrators have gained significant share due to their cost-effectiveness and on-site oxygen generation capability, while portable devices are the fastest-growing sub-segment driven by patient mobility preferences. Regionally, North America dominates the medical oxygen market with over 37% of global share, supported by advanced healthcare systems and high chronic disease prevalence. Asia-Pacific is emerging as the fastest-growing regional market, driven by improving healthcare access, rising air-quality-related respiratory issues, and expanding home care infrastructure, while Europe holds a steady share supported by an aging population and established reimbursement frameworks.

• •North America held over 37% of global medical gases market share in 2025; regional medical oxygen segment projected at ~$1.26 billion in 2024 growing at 5.4% CAGR through 2031
• •Key product segments include oxygen concentrators, compressed gas cylinders, liquid oxygen systems, and consumables such as masks and nasal cannulas
• •Asia-Pacific is the fastest-growing region, driven by rising respiratory disease burden, expanding healthcare infrastructure, and growing home care adoption

Who are the notable companies in the industry?

The competitive structure of the oxygen therapy market is characterized by moderate consolidation, with a relatively small number of large-scale integrated industrial gas producers controlling much of the medical-grade oxygen supply chain alongside a broader field of specialty medical device manufacturers focused on concentrator and delivery system design. Integrated producers benefit from vertically integrated operations spanning air separation units, bulk oxygen production, and cylinder filling infrastructure, giving them significant advantages in scale and distribution reach. Specialty producers tend to focus on downstream oxygen delivery devices, concentrators, portable systems, and accessories, and compete on technological differentiation, regulatory compliance, and channel partnerships with hospitals and home care providers. Global oxygen production capacity is concentrated in North America, Europe, and East Asia, where large air separation facilities serve both industrial and medical customers, with increasing investment in on-site generation systems reducing dependency on bulk supply logistics.

• •Market is moderately consolidated at the supply-chain level: integrated gas producers control bulk oxygen generation while specialty device makers dominate downstream equipment
• •Two primary process routes: cryogenic air separation for large-scale bulk oxygen and pressure swing adsorption (PSA) technology for on-site concentrator generation
• •Capacity is concentrated in North America, Europe, and East Asia, with emerging markets increasingly relying on regional air separation investments and cylinder import networks

What are the recent trends and outlook?

The market is experiencing a structural shift toward home-based and ambulatory oxygen therapy as technological improvements in portable concentrator weight, battery life, and noise levels make at-home and out-of-home use increasingly viable for a broader patient population. Digital health integration, including oxygen monitoring via connected devices, remote patient management platforms, and telehealth-enabled titration, is becoming an increasingly important value differentiator for newer product offerings. Sustainability pressures and the energy intensity of cryogenic separation are prompting innovation in more efficient PSA concentrator designs and recycling of oxygen carrier materials. Through 2030 and beyond, the market is expected to continue its steady 5%-plus growth trajectory as aging demographics, respiratory disease prevalence, and healthcare cost containment favoring home care converge to sustain demand across all major regions.

• •Portable and lightweight oxygen concentrators are increasingly preferred for patient mobility, driving product development toward smaller, battery-optimized designs
• •Connected oxygen monitoring and telehealth integration are emerging as competitive differentiators, enabling remote dosage management and reduced hospital readmissions
• •Market projected to reach approximately $70 billion by 2035 on some trajectories, with home care and Asia-Pacific regions as key growth contributors